PPARG and metabolic syndrome: Although PPAR-γ signaling may reduce M1 (and M2b) inflammatory cytokine production and potentiate M2a alternative activation, results suggest that it also impedes M2c polarization and restoration of fully anti-inflammatory conditions in chronic settings like metabolic syndrome and autoimmune diseases.